Erasca’s Innovative RAS/MAPK Pathway Targeting and Promising Preclinical Data Earns Buy Rating

H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on Erasca (ERAS – Research Report) today and set a price target of $6.00.

Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight Erasca’s innovative approach in targeting the RAS/MAPK pathway. At the AACR 2025 meeting, Erasca presented promising preclinical data from its RAS-targeting programs, showcasing their potential to be first- or best-in-class treatments. This includes ERAS-0015, which demonstrated superior binding affinity and potency compared to existing therapies, indicating strong potential for treating RAS mutant solid tumors.
Another factor contributing to the Buy rating is the performance of ERAS-4001, a selective pan-KRAS inhibitor that showed significant tumor growth inhibition and synergy with other treatments in preclinical models. Additionally, Erasca’s novel SHOC2 SMP complex inhibitors represent a groundbreaking approach to overcoming adaptive resistance in RAS-driven tumors. These strategic developments underscore Erasca’s commitment to advancing precision oncology, making its stock an attractive investment opportunity.

In another report released on April 28, Bank of America Securities also maintained a Buy rating on the stock with a $5.00 price target.